Vesselon

Rhodemann Li
T 203-989-0500
Company website http://www.vesselon.com
rhodemann.li@vesselon.com

Industry:
__X__Pharma
__X__Biotech
_____Medical Device
_____Diagnostic
_____Other (declare)

Management:

- **Executive Leadership**

Clay Larsen, President & CEO
Rhodemann Li, EVP Strategy & Finance
Elisa Konofagou, PhD, CSA
Ernest Schutt, MS, CTA

- **Board**

Jon Serbousek, Chrmn; Pinnacle Advisory Partners, ex-Biomet, ex-Medtronic
Juergen Raths, MD, Director, ex-Eli Lilly
Paul Latchford, Director, CEO ST Media & Comm. Group
Clay Larsen, Director
Rhodemann Li, Director

- **Scientific Advisory Board**

Manuel Hidalgo, MD, Beth Israel Deaconess
Eileen O'Reilly, MD, Memorial Sloan Kettering Cancer Center

Number of Employees:
3

Finance:

- **Auditor**

N.A.

- **Financing to Date**

$7M NIH/NSF pre clinical testing
$1M Series A Preferred
$1M Bridge Note

Executive Summary:

Triple Negative Breast (TNBC), Pancreatic (PDAC) cancer, Parkinson's and Alzheimer's are deadly or debilitating in part because therapeutic drugs cannot reach their target. Vesselon's platform gets small or large molecule drugs directly to the target by temporarily opening nanoscale pores in vessels using a repurposed FDA-approved microbubble (MB).

Company History and Team:

Incorporated in Delaware 2012

Clay Larsen President, CEO. Co-founder, Vesselon. Senior management at FujiFilm and Acuson.

Rhodemann Li, EVP. Founder, Vesselon. Co-founder, Li Medical Technologies.

Dr. Elisa Konofagou CSA, Inventor, Columbia Ultrasound Elasticity Imaging Laboratory, world expert on ultrasound and MBs to enhance drug delivery.

Dr. Ernest Schutt Inventor. CTA, 59 patents in MB field. Vesselon MB inventor.

Market Opportunity / Unmet Need:

53,000 people annually will be diagnosed with pancreatic cancer in US. The mortality rate is 71% within the first year and 92% within 5 years.

Products/Services – Launched & Pipeline:

Vesselon owns an FDA-approved diagnostic MB for which the Company is seeking new therapeutic indications – drug delivery. Vesselon intends to file a U.S. FDA Investigational New Drug (IND) application for a proprietary MB/drug combination in 2019 to gain approval to begin clinical trials in TNBC and PDAC.

Commercial / Technical Milestones:

Clinical data showed (Dimcevski 2016) **doubled median overall survival** for MB-treated PDAC patients **to 18 months,** from **9 months.** 231 patients treated with MBs to enhance standard of care therapy in PDAC, glioblastoma, and stroke safely with strong signal of activity.

Intellectual Property:

Patents issued/pending (including composition of matter)

Competition:

Only 3 other FDA-approved MBs, however, they are owned by companies that currently are exclusively diagnostic.

Exit:

Vesselon intends to out-license indications to or be acquired by pharma partner(s).